Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsPreferred Shares RepurchasedShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Gains from Sales and Divestitures (2016 - 2023)

PharmaCyte Biotech (PMCB) has disclosed Gains from Sales and Divestitures for 9 consecutive years, with $3935.0 as the latest value for Q2 2023.

  • Quarterly Gains from Sales and Divestitures fell 41.6% to $3935.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $3935.0 through Apr 2023, down 41.6% year-over-year, with the annual reading at $3935.0 for FY2023, 41.6% down from the prior year.
  • Gains from Sales and Divestitures for Q2 2023 was $3935.0 at PharmaCyte Biotech, roughly flat from $3935.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $11.4 million in Q4 2019, with the low at $2102.0 in Q3 2022.
  • Average Gains from Sales and Divestitures over 5 years is $2.2 million, with a median of $5221.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures skyrocketed 484.62% in 2019, then plummeted 41.6% in 2023.
  • Over 5 years, Gains from Sales and Divestitures stood at $11.4 million in 2019, then fell by 0.88% to $11.3 million in 2020, then plummeted by 99.97% to $3703.0 in 2021, then fell by 0.92% to $3669.0 in 2022, then grew by 7.25% to $3935.0 in 2023.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $3935.0, $3935.0, and $3669.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.